Outcome of kidney transplants from viremic and non-viremic hepatitis C virus positive donors into negative recipients: results of the Spanish registry

Franco, Antonio; Moreso, Francesc; Solà Porta, Eulàlia; Beneyto, Maria Isabel; Esforzado, Núria; González-Roncero, Francisco; Sancho-Calabuig, Asunción; Melilli, Edoardo; Ruiz San Millán, Juan Carlos; Galeano, Cristina; Renal Transplantation with HCV Positive Donors Spanish Study Group

doi:http://dx.doi.org/10.3390/jcm12051773

Outcome of kidney transplants from viremic and non-viremic hepatitis C virus positive donors into negative recipients: results of the Spanish registry

License

Citation

Franco A, Moreso F, Solà-Porta E, Beneyto I, Esforzado N, Gonzalez-Roncero F, et al. Outcome of kidney transplants from viremic and non-viremic hepatitis C virus positive donors into negative recipients: results of the Spanish registry. J Clin Med. 2023 Feb 23;12(5):1773. DOI: 10.3390/jcm12051773

Abstract

Historically, donor infection with hepatitis-C virus (HCV) has been a barrier to kidney transplantation. However, in recent years, it has been reported that HCV positive kidney donors transplanted into HCV negative recipients offer acceptable mid-term results. However, acceptance of HCV donors, especially viremic, has not broadened in the clinical practice. This is an observational, multicenter, retrospective study including kidney transplants from HCV positive donors into negative recipients reported to the Spanish group from 2013 to 2021. Recipients from viremic donors received peri-transplant treatment with direct antiviral agents (DAA) for 8–12 weeks. We included 75 recipients from 44 HCV non-viremic donors and 41 from 25 HCV viremic donors. Primary non function, delayed graft function, acute rejection rate, renal function at the end of follow up, and patient and graft survival were not different between groups. Viral replication was not detected in recipients from non-viremic donors. Recipient treatment with DAA started pre-transplant avoids (n = 21) or attenuates (n = 5) viral replication but leads to non-different outcomes to post-transplant treatment with DAA (n = 15). HCV seroconversion was more frequent in recipients from viremic donors (73% vs. 16%, p < 0.001). One recipient of a viremic donor died due to hepatocellular carcinoma at 38 months. Donor HCV viremia seems not to be a risk factor for kidney transplant recipients receiving peri-transplant DAA, but continuous surveillance should be advised.